Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submi
about
Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Cardio-oncology: Concepts and practicePrevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprololGetting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer TherapyThe tell-tale heart: molecular and cellular responses to childhood anthracycline exposureCardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next LevelEvaluation and management of patients with heart disease and cancer: cardio-oncologyCardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and ManagementCardiac risk in the treatment of breast cancer: assessment and management.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsBNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculographyCancer treatment-related cardiac toxicity: prevention, assessment and management.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionCancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Cardio-oncology: what you need to know now for clinical practice and echocardiography.Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?Cardiovascular disease in adult survivors of childhood cancer.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represAn update on cardio-oncology.Cardiotoxicity and oncological treatments.Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatmentThe role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicityUtilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?Losartan treatment attenuates tumor-induced myocardial dysfunctionCuring Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.Cardiovascular Complications of Hematopoietic Stem Cell Transplantation.Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort studyA recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of CardiologyBenefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.Cardiotoxicity Following Cancer Treatment.Anthracycline Chemotherapy and Cardiotoxicity.Heart transplantation in pediatric cardiomyopathies.Chemotherapy-related cardiomyopathy: a neglected aspect of cancer survivorship.Cardiomyopathy associated with cancer therapy.
P2860
Q26742059-73078211-74AC-4DC3-BCA0-5426147AC4D8Q26750878-1C8F0670-4ABB-4331-AD76-84E500C2F670Q26768272-41668EF3-3629-4501-AE49-38D1A28A5327Q26797138-6859E610-F973-4860-A6A8-9955764AB765Q26823592-32099380-7864-4AD8-978E-17673FF2580AQ26864094-516B9E1D-AB26-4ABC-BA5C-9FB842A277D5Q26998273-0F2F3C0C-4742-4E45-A3A7-CC2BEDBF3049Q28068290-DABD59DA-8E03-4486-A406-561152D84762Q28081385-DCDEADA4-C230-4041-92AA-687FCAE49A2CQ28087776-574A4906-2FB9-409F-965D-AC8A64262182Q28538548-22E3E085-0245-4AD4-ABF9-031E83954ECCQ30276456-38F1130B-1C21-4685-A115-4E978453C452Q30399577-520D10A6-6E12-4B73-A07E-991F8B4F1317Q30426853-6488E9EB-B8CE-41DA-9CFD-72DA7C347A06Q33701308-C1CD5C2C-B1BD-4C8A-A422-5FF0294ED345Q33988329-897FF8C1-AB9C-47C8-844E-CC4376ADBB99Q34042984-189DAB5F-9813-4F05-830A-D51D06983E69Q34046881-C9A1CC7B-57AD-4131-A972-45CBC7262877Q34650059-B9EB2B22-EA07-4FC2-9C07-092D62A618A2Q34660647-090AF373-A904-4C0C-B25A-DBC93B821101Q35024342-D0F0CC33-0B31-4700-BBBC-D1CB98DDE6DDQ35368603-E74851E9-9919-4A7D-8B56-FB0CAF0AD7DAQ35588736-E413BC25-4C4C-4341-A0AA-A561CF4E43C6Q35843555-616EFEB9-EFF9-4BAD-8D15-2CC7F72444EEQ35931497-26E31FCE-9091-4996-80D6-BD8F903AD49AQ35997676-357F4B87-817E-4B2E-A1F4-E3DC0460655DQ36099606-2B09752C-C06D-44E6-A630-54AAF0EBD26EQ36212048-20059E4D-3956-4A56-8890-D2127F5EC1AAQ36551901-A55AD658-6707-4B9F-92B9-56599A289EB6Q36615092-EBA1876D-A59E-44DF-9AEE-14420560D524Q36900970-55CD28B8-3AFA-4E3B-ACF7-6D5E92F09334Q37052852-F1187B13-F4EB-475A-B594-7A14E5B36CECQ37311943-CEEC4729-4B2C-441A-AFC8-1FFEC4E99EEBQ37563014-9FB0D34D-3EB5-41AC-9EEB-AB07B9D13DF5Q37648395-664CAFCD-DF4E-4A62-A9CE-658B17C90314Q37663263-B7807087-8025-4F30-9FCF-B84C8D37DB51Q37694541-C8246C7A-629E-4F73-AE86-6D7C5B850979Q38161524-CE3B4B9B-7CB3-4A77-8475-B71D56A7F829Q38231301-5697CC08-789E-4B58-B281-2594C8672DADQ38242641-FC13A9D5-09B1-4A4A-B6A6-9D262A7387EE
P2860
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submi
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Enalapril and carvedilol for p ...... d caRvedilol in patients submi
@en
Enalapril and carvedilol for p ...... emopathies: the OVERCOME trial
@nl
type
label
Enalapril and carvedilol for p ...... d caRvedilol in patients submi
@en
Enalapril and carvedilol for p ...... emopathies: the OVERCOME trial
@nl
prefLabel
Enalapril and carvedilol for p ...... d caRvedilol in patients submi
@en
Enalapril and carvedilol for p ...... emopathies: the OVERCOME trial
@nl
P2093
P921
P1476
Enalapril and carvedilol for p ...... ment of Malignant hEmopathies)
@en
P2093
Ariadna Domènech
Jordi Esteve
José T Ortiz-Pérez
Marta Sitges
Montserrat Rovira
Rosario J Perea
Teresa M de Caralt
Xavier Bosch
P304
P356
10.1016/J.JACC.2013.02.072
P407
P577
2013-04-10T00:00:00Z